B
ladder cancer is the fourth most commonly diagnosed cancer in U.S. men and the 10th most commonly diagnosed cancer in U.S. women (1) . Standard methods for diagnosis of bladder cancer involve cytologic evaluation of urine, imaging tests, and cystoscopy (2, 3) . Because cystoscopy is uncomfortable and costly, alternative diagnostic methods have been sought. Urine-based biomarkers have been developed as potential alternatives or adjuncts to standard tests for the initial diagnosis of bladder cancer or identification of recurrent disease (4) .
Six urinary biomarkers have been approved by the U.S. Food and Drug Administration (FDA) for diagnosis or surveillance of bladder cancer: quantitative nuclear matrix protein 22 (NMP22) (Alere NMP22 ). The qualitative NMP22 and BTA tests can be performed as point-of-care tests, and the others are performed in a laboratory. One additional test, Cxbladder (Pacific Edge Diagnostics USA), is a "laboratory-developed test" that does not require FDA approval. Other biomarkers have been developed but are not FDA-approved.
The purpose of this study was to systematically review the evidence on the comparative accuracy of urinary biomarkers for diagnosis of bladder cancer. It was done as part of a larger review (5) on the evaluation and treatment of non-muscle-invasive bladder cancer that was nominated to the Agency for Healthcare Research and Quality (AHRQ) by the American Urological Association for use in updating its guidelines.
protocol was developed using a standardized process (6) with input from experts and the public and is registered in the PROSPERO database (7) . This article focuses on the accuracy of urinary biomarkers for initial diagnosis of bladder cancer or for diagnosis of recurrent disease, including any variance in diagnostic accuracy based on tumor characteristics, patient characteristics, or the nature of presenting signs or symptoms.
Data Sources and Searches
A research librarian searched multiple electronic databases, including Ovid MEDLINE (January 1990 through June 2015), the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews (through June 2015). We also reviewed reference lists and searched ClinicalTrials.gov.
Study Selection
Two investigators independently reviewed abstracts and full-text articles against prespecified eligibility criteria. We included cross-sectional and cohort studies on the diagnostic accuracy of urinary biomarkers in adults who had signs or symptoms of bladder cancer or were undergoing surveillance for recurrent disease after treatment. We focused on urinary biomarkers approved by the FDA for the diagnosis of bladder cancer (quantitative or qualitative NMP22, qualitative or quantitative BTA, FISH, and ImmunoCyt) or classified by the FDA as a laboratory-developed test (Cxbladder). We excluded studies that used a casecontrol design; studies that did not evaluate the diagnostic accuracy of biomarkers against standard diagnostic methods (cystoscopy and histopathology); and studies on the accuracy of biomarkers for screening in assessing prognosis, guiding therapy, or monitoring response to treatment.
Data Extraction and Quality Assessment
One investigator extracted details about the setting, tests evaluated, definition of a positive test result, study design, reference standard, inclusion criteria, population characteristics, proportion found to have bladder cancer, bladder cancer stage and grade, results, and funding sources. We constructed 2 × 2 tables with the number of true-positive, false-positive, truenegative, and false-negative results from published sample sizes, prevalence, sensitivity, and specificity. A second investigator verified extractions for accuracy.
Two investigators independently assessed the risk of bias for each study as low, moderate, or high using criteria adapted from QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies 2) (8) . Discrepancies were resolved through discussion and consensus.
Data Synthesis and Analysis
We performed meta-analyses for sensitivity and specificity using a bivariate logistic mixed-effects model (9) with SAS, version 10.0 (SAS Institute) (10) . We assumed random effects with a bivariate normal distribution and measured statistical heterogeneity with the random-effects variance ( 2 ) . When few studies were available for an analysis, we used the moment estimates of correlation between sensitivity and specificity in the bivariate model. We calculated positive and negative likelihood ratios (LRs) using the summarized sensitivity and specificity (11, 12) . Because studies of a particular biomarker generally used the same definition for a positive test result, we did not plot summary receiveroperating characteristic curves (13) . For head-to-head comparisons, we used the same bivariate logistic mixed-effects model, with an added indicator variable for the tests.
We conducted analyses for each biomarker by using data from all patients and data stratified according to whether testing was performed for initial diagnosis (evaluation of symptoms) or diagnosis of recurrence (surveillance). We also performed analyses stratified by study design features (such as retrospective or prospective or use of a prespecified threshold to define a positive test result), risk of bias (overall and whether the study performed blinding to the results of the index test), the country in which the study was conducted, and tumor grade and stage (14) .
We assessed the strength of evidence (SOE) for each body of evidence as high, moderate, low, or insufficient based on aggregate study quality, precision, consistency, and directness.
Role of the Funding Source
This project was funded under contract HHSA290201200014I from the AHRQ, U.S. Department of Health and Human Services. AHRQ staff assisted in developing the scope and key questions. The AHRQ had no role in study selection, quality assessment, or synthesis.
RESULTS
The literature flow diagram (Figure 1 ) summarizes the search and selection of articles. Database searches resulted in 4358 potentially relevant articles. After dual review of abstracts and titles, we selected 262 articles for full-text dual review and determined that 57 studies (in 60 publications) met our inclusion criteria (Appendix Table 1 , available at www.annals.org) . Nineteen studies evaluated quantitative NMP22, 4 evaluated qualitative NMP22, 23 evaluated qualitative BTA, 4 evaluated quantitative BTA, 10 evaluated FISH, 13 evaluated ImmunoCyt, and 1 evaluated Cxbladder. Sample sizes ranged from 26 to 3916, mean age ranged from 54 to 77 years, the proportion of male patients ranged from 57% to 88%, and the proportion diagnosed with bladder cancer ranged from 3% to 81%. Eight studies focused on diagnostic testing for signs and symptoms suggestive of bladder cancer, 16 focused on surveillance of previously treated bladder cancer, and 19 evaluated mixed populations. Forty-three studies were conducted in the United States or Europe. We rated 2 studies as having low risk of bias (20, 21) , 3 as having high risk of bias (25, 62, 68) , and the remainder as having medium risk of bias. Frequent methodological shortcomings were failure to report blinded interpretation of the reference standard, failure to report enrollment of a random or consecutive sample of patients, or failure to report predefined criteria for a positive test result.
Quantitative NMP22
Sensitivity of quantitative NMP22 was 0.69 (95% CI, 0.62 to 0.75), and specificity was 0.77 (CI, 0.70 to 0.83) (19 studies), for a positive LR of 3.05 (CI, 2.28 to 4.10) and a negative LR of 0.40 (CI, 0.32 to 0.50) (Appendix Figure 1 , available at www.annals.org). Exclusion of 2 studies that used a cutoff other than >10 U/mL for a positive test result (18, 37) resulted in similar sensitivity and specificity. Diagnostic accuracy was similar for evaluation of symptoms and for surveillance. Excluding 1 study with high risk of bias (68) and restricting the analysis to prospective studies, those conducted in the United States or Europe, or those that used a prespecified threshold for a positive test result had little effect on pooled estimates. Restricting the analysis to 3 studies with blinded reference standard interpretation resulted in higher specificity (0.89 [CI, 0.78 to 0.95]) (15, 42, 58) .
Qualitative NMP22
Sensitivity of qualitative NMP22 was 0.58 (CI, 0.39 to 0.75), and specificity was 0.88 (CI, 0.78 to 0.94) (4 studies), for a positive LR of 4.89 (CI, 3.23 to 7.40) and a negative LR of 0.48 (CI, 0.33 to 0.71) (Appendix Figure 2 , available at www.annals.org) (20, 21, 23, 37 
Quantitative BTA
Sensitivity of quantitative BTA was 0.65 (CI, 0.54 to 0.75), and specificity was 0.74 (CI, 0.64 to 0.82) (4 studies), for a positive LR of 2.52 (CI, 1.86 to 3.41) and a negative LR of 0.47 (CI, 0.37 to 0.61) (Appendix Figure  4 , available at www.annals.org) (19, 27, 54, 68) . Estimates were similar in 3 studies that used a threshold greater than 14 U/mL for a positive test result (27, 54, 68) and when 1 study with high risk of bias was omitted (68).
FISH
Sensitivity of FISH was 0.63 (CI, 0.50 to 0.75), and specificity was 0.87 (CI, 0.79 to 0.93) (11 studies), for a positive LR of 5.02 (CI, 2.93 to 8.60) and a negative LR of 0.42 (CI, 0.30 to 0.59) (Appendix Figure 5 , available at www.annals.org). Estimates were similar when 1 study with high risk of bias (25) was excluded and when the analysis was restricted to studies that used a prospective design or reported interpretation of the reference standard blinded to FISH results. For surveillance, sensitivity was 0.55 (CI, 0.36 to 0.72) and specificity was 0.80 (CI, 0.66 to 0.89). For evaluation of symptoms, sensitivity of FISH was 0.73 (CI, 0.50 to 0.88) (40, 69). Only 1 study reported specificity for evaluation of symptoms (0.95 [CI, 0.87 to 0.98]) (69).
ImmunoCyt
Sensitivity of ImmunoCyt was 0.78 (CI, 0.68 to 0.85), and specificity was 0.78 (CI, 0.72 to 0.82) (14 studies), for a positive LR of 3.49 (CI, 2.82 to 4.32) and a negative LR of 0.29 (CI, 0.20 to 0.41) (Appendix Figure 6 , available at www.annals.org). Excluding 1 study with high risk of bias (71) and restricting the analysis to prospective studies had little effect on the estimates. For evaluation of symptoms, sensitivity was 0.85 (CI, 0.78 to 0.90) and specificity was 0.83 (CI, 0.77 to 0.87) (31, 35, 59, 63, 64, 66, 67); for surveillance, sensitivity Table  2 , available at www.annals.org) (37).
Head-to-Head Comparisons
Relatively few studies directly compared the diagnostic accuracy of different urinary biomarkers against cystoscopy and biopsy in the same population (Appendix Table 3 Evidence on other head-to-head comparisons of urinary biomarkers was based on 1 or 2 studies, which precluded reliable conclusions about comparative test performance (Appendix Table 3 ).
Sixteen studies found that various urinary biomarkers plus cytologic evaluation were associated with higher sensitivity than the biomarker alone (0. Table 3 ). Results were similar in a subgroup of 8 studies of ImmunoCyt plus cytologic evaluation versus ImmunoCyt alone. We found no clear differences in sensitivity for tumor stage Ta or T1 or low-grade bladder cancer (16, 33, 35, 64, 70 -73) .
Tumor Stage and Grade
Across urinary biomarkers, sensitivity increased with higher tumor stage (Appendix Table 4 , available at www.annals.org). For quantitative NMP22, qualitative BTA, and FISH, differences in sensitivity ranged from 0.23 to 0.30 between T1 and Ta tumors and from 0.10 to 0.15 between T2 or higher-stage tumors and T1 tumors. Sensitivity for carcinoma in situ was similar to or slightly lower than sensitivity for T1 tumors. For ImmunoCyt, the association between higher tumor stage and increased sensitivity was less clear. Sensitivity was 0.74 for Ta tumors (CI, 0.63 to 0.83) and increased to 0.81 for T1 and T2 or higher-stage tumors.
Sensitivity also increased with higher tumor grade (Appendix Table 4 ). For quantitative NMP22, qualitative BTA, and FISH, differences in sensitivity ranged from 0.14 to 0.28 between G2 and G1 tumors and from 0.16 to 0.21 between G3 and G2 tumors. For ImmunoCyt, differences based on tumor grade were less pronounced, with sensitivity of 0.74 (CI, 0.66 to 0.80) for low-grade tumors and 0.83 (CI, 0.78 to 0.88) for highgrade tumors, for a difference of 0.10 (CI, 0.03 to 0.17).
We observed similar associations with tumor stage and grade for other urinary biomarkers (Appendix Table 4). However, estimates were based on smaller numbers of studies and were less precise, and differences were not always statistically significant.
One study that stratified data by tumor size found higher sensitivity of qualitative BTA for tumors measuring 2 to 5 cm (0.96) and larger than 5 cm (1.0) than for tumors smaller than 2 cm (0.60) (P < 0.001) (41). Another study found higher sensitivity of FISH for tumors measuring 1 to 3 cm (0.93) or larger than 3 cm (0.94) than for tumors smaller than 1 cm (0.46) (P = 0.001) (40). One study that stratified data by the number of tumors found that quantitative and qualitative NMP22 and Cxbladder were each associated with higher sensitivity for multifocal versus unifocal tumors, although differences were not statistically significant (37).
Patient Characteristics
Few studies evaluated effects of patient characteristics on the diagnostic accuracy of urinary biomarkers. Diagnostic accuracy did not clearly differ according to sex, age, smoking status, or receipt of prior intravesical therapy (20, 37, 43, 50) . Diagnostic accuracy of ImmunoCyt was similar in studies that specifically enrolled patients with microscopic or macroscopic hematuria (59, 66, 67) and studies that enrolled patients with various signs or symptoms of bladder cancer.
Eight studies of various urinary biomarkers did not find consistent differences in specificity according to such factors as presence of other urological cancer types, renal calculi, prostatitis, benign prostatic hypertrophy, urinary tract infection, or hematuria, although specificity was higher in some studies when other urological conditions were not present (35, 37, 52, 54, 62, 66, 67, 74).
DISCUSSION
Urinary biomarkers were associated with sensitivities for bladder cancer that ranged from 0.57 to 0.82 ( Figure 2 ) and specificities that ranged from 0.74 to 0.88 (Figures 2 and 3 and Appendix Table 2 ). Strengthof-evidence ratings are shown in Table 1 . Positive LRs ranged from 2.52 to 5.53, and negative LRs ranged from 0.21 to 0.48 (75). Findings were robust in sensitivity and stratified analyses. Evidence was strongest for quantitative NMP22, qualitative BTA, FISH, and ImmunoCyt (moderate SOE) and relatively sparse for other biomarkers (low SOE). Across urinary biomarkers, sen-sitivity was greater for higher-stage and higher-grade tumors (high SOE). For qualitative BTA, FISH, and ImmunoCyt, sensitivity was higher for initial diagnosis in persons with signs or symptoms of bladder cancer than for diagnosis of recurrence. However, accuracy did not differ by testing indication for quantitative NMP22. Studies that directly compared the accuracy of quantitative NMP22 and qualitative BTA found no differences in diagnostic accuracy (moderate SOE). ImmunoCyt was associated with higher sensitivity than FISH (difference, 0.11) but lower specificity (difference, 0.08), based on 3 studies (low SOE). Head-to-head comparisons of other urinary biomarkers were too limited to reach firm conclusions about comparative accuracy. Sensitivity increased with the use of urinary biomarkers in conjunction with cytologic evaluation versus the biomarkers alone (moderate SOE). Findings were relatively robust in sensitivity and subgroup analyses based on study quality, variability in test cutoffs, country, and other factors.
Our findings on diagnostic accuracy were consistent with those of prior systematic reviews (76 -78). Strengths of our review include the exclusion of casecontrol studies, which can overestimate diagnostic accuracy (79); use of bivariate binomial models to pool data that account for the correlation between sensitivity and specificity (12) ; incorporation of more recently published studies; separate analyses of head-to-head comparisons (14) ; and evaluation of subgroups based on patient and tumor characteristics.
As detailed in the full report, no studies have evaluated effects on clinical outcomes of using urinary bio- 
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Urinary Biomarkers for Diagnosis of Bladder Cancer markers (5). Therefore, decisions about their use must be made on the basis of diagnostic test performance. Table 2 shows estimated probabilities for bladder cancer after use of urinary biomarkers, based on LRs calculated from pooled sensitivities and specificities. The observed LRs generally fell within the range indicating relatively small changes in the probability that a patient does or does not have bladder cancer (75). Urinary biomarkers miss 18% to 43% of patients with bladder cancer and yield false-positive results in 12% to 26% of patients without bladder cancer. The value of urinary biomarkers and whether they are sufficiently accurate to reduce the need for cystoscopy depends on the clinician's ability to estimate the pretest probability of disease, the importance to patients and clinicians of relatively small changes in the probability of bladder cancer, and the acceptable threshold and clinical consequences of missed or delayed diagnoses and falsepositive results. Obtaining urinary biomarkers in combination with cytologic evaluation would increase the sensitivity but would still result in about 10% of cases being missed. Our review had limitations. As in other metaanalyses of diagnostic accuracy, substantial statistical heterogeneity was present in most pooled analyses (80 -82). To address anticipated heterogeneity, we used random-effects models to pool studies; stratified studies according to the reason that testing was done; and performed additional analyses based on study design and test, patient, and tumor characteristics. We also performed separate analyses based on head-tohead comparisons of biomarkers, which tended to be associated with less heterogeneity than pooled acrossstudy estimates. A limitation of our analysis of withingroup comparisons is that we had to treat the compared groups independently because we had only aggregated data, which might have resulted in overly wide CIs. However, point estimates indicated little difference between tests. We also excluded non-Englishlanguage articles and did not search for studies published only as abstracts; focused on FDA-approved tests or laboratory-developed tests; and did not evaluate other potential uses of biomarkers, such as evaluation of cytologic atypia, determination of prognosis, guidance for treatment, or assessment of recurrence risk (83, 84). Limitations of the evidence base include few studies for biomarkers other than quantitative NMP22, qualitative BTA, FISH, and ImmunoCyt. In addition, almost all studies on the diagnostic accuracy of biomarkers had methodological shortcomings. Few studies evaluated effects of patient characteristics, such as age, sex, race, or presence of other urological conditions, on diagnostic test performance. More research is needed to understand optimal combinations of urinary biomarkers with or without cytologic evaluation and to evaluate sequences of diagnostic tests applied in prespecified algorithms, including the effect on use of cystoscopy and clinical outcomes.
In conclusion, urinary biomarkers miss a substantial proportion of patients with bladder cancer and yield false-positive results in others. Diagnostic accuracy may be slightly higher for initial diagnosis of bladder cancer in patients with signs and symptoms than for surveillance, and accuracy is poor for low-stage and lowgrade tumors. Urinary biomarkers in combination with 
